If you've spent any time in the antimicrobial peptide literature, LL-37 keeps showing up — in bacterial-membrane studies, in wound-healing models, in psoriasis and rosacea research, sometimes all three in the same paper. That range is exactly what makes LL-37 confusing to someone encountering it for the first time: it doesn't fit neatly into one category the way a single-mechanism compound does.
Featured Product
This guide sorts that out. You'll get a clear definition of LL-37 and where it comes from in the body, a breakdown of how it actually works against bacteria and biofilms, its role in immune modulation and wound-healing research, how it compares to defensins and other host-defense peptides, and what to look for when sourcing a research-grade LL-37 peptide — purity verification, storage, and reconstitution included.
What Is LL-37?
LL-37 is a 37-amino-acid host-defense peptide belonging to the cathelicidin family, studied for its antimicrobial, immune-modulating, and wound-healing properties in laboratory research. It's the only cathelicidin peptide expressed in humans, generated by proteolytic cleavage of its precursor protein, hCAP-18. Its name comes directly from its structure: it begins with two leucine (L) residues and contains 37 amino acids total.
The Biology of LL-37: From hCAP-18 to Active Peptide
Cathelicidin Family and Genetic Origin
LL-37 is produced from the CAMP gene, which encodes the precursor protein hCAP-18. Neutrophils, macrophages, and epithelial cells — including keratinocytes in the skin — store and release hCAP-18, which is then cleaved by proteinase 3 to release the active LL-37 peptide. This places LL-37 squarely within the innate immune system, the body's fast-acting, non-specific first line of defense against pathogens.
Molecular Structure
Structurally, LL-37 is a cationic, amphipathic alpha-helical peptide — meaning it carries a net positive charge and folds into a helix with hydrophobic and hydrophilic faces on opposite sides. That amphipathic design is central to how it interacts with bacterial membranes, which are negatively charged and structurally distinct from human cell membranes.
Key takeaway: LL-37's antimicrobial and immune-signaling functions both trace back to the same structural feature — its amphipathic helix — which is why the peptide shows up across so many different areas of host-defense research.
How LL-37 Fights Bacteria: Mechanism of Action
LL-37's antimicrobial activity in research models centers on direct interaction with bacterial membranes, distinct from how conventional antibiotics work.
Membrane Disruption
LL-37's positive charge draws it toward the negatively charged membranes of both gram-positive and gram-negative bacteria. Once bound, its amphipathic structure allows it to insert into the lipid bilayer, disrupting membrane integrity and ultimately causing bacterial cell death. Because this mechanism targets the membrane directly rather than a specific enzyme or protein target, it's a structural vulnerability that's harder for bacteria to evolve resistance against — a major reason LL-37 is studied in antimicrobial-resistance research.
Biofilm Disruption
Beyond killing free-floating bacteria, LL-37 has been studied for its ability to interfere with biofilm formation and to disrupt existing biofilms — the structured bacterial communities that are notoriously resistant to conventional antibiotics. Research models have also examined LL-37's capacity to bind and neutralize lipopolysaccharide (LPS), the endotoxin found on gram-negative bacterial membranes, adding an anti-inflammatory dimension to its antimicrobial profile.
LL-37 vs. Other Antimicrobial Peptides
LL-37 is frequently studied alongside human defensins, another major class of antimicrobial host-defense peptides. Here's how the two compare at a structural and functional level.
Factor | LL-37 (Cathelicidin) | Human Defensins |
Peptide family | Cathelicidin (single human member) | Defensin family (alpha- and beta-defensins) |
Structure | Amphipathic alpha-helix | Beta-sheet structure stabilized by disulfide bonds |
Primary source cells | Neutrophils, macrophages, keratinocytes | Neutrophils, epithelial cells (varies by defensin type) |
Mechanism | Membrane disruption, LPS binding, immune signaling | Primarily membrane disruption, some immune signaling |
Research focus areas | Wound healing, inflammation, biofilm disruption | Mucosal immunity, gut and skin barrier research |
Featured-snippet answer: LL-37 is a cathelicidin-family host-defense peptide with an alpha-helical structure, while human defensins are a separate peptide family with a beta-sheet structure stabilized by disulfide bonds. Both are antimicrobial, but they differ in structure, source cells, and the breadth of immune-signaling roles studied in the research literature.
LL-37's Role in Immune Modulation and Anti-Inflammatory Research
LL-37 isn't studied purely as an antimicrobial agent — a substantial part of the literature focuses on its role as an immune signaling molecule. It has been shown in research models to act as a chemoattractant, recruiting neutrophils and other immune cells to sites of infection or injury, and to activate macrophages. It also interacts with formyl peptide receptor 2 (FPR2) on immune cells, a receptor implicated in chemotaxis and inflammatory signaling.
This dual identity — direct antimicrobial action plus immune-system signaling — is why LL-37 is studied in inflammatory and autoimmune skin conditions including psoriasis, rosacea, and atopic dermatitis research, where cathelicidin expression levels are frequently examined as part of disease mechanism studies.
LL-37 in Wound-Healing Research
Wound healing is one of the most active areas of LL-37 research, and the peptide's proposed role spans several stages of the repair process:
- Keratinocyte proliferation — studied for its effect on skin cell growth during re-epithelialization
- Angiogenesis — examined for a possible role in promoting new blood vessel formation at wound sites
- Chronic wound research — cathelicidin expression patterns are studied in chronic, non-healing wound models
- Fibroblast activity and collagen deposition — relevant to tissue regeneration research
Because infection and delayed healing are closely linked in chronic wound research, LL-37's combined antimicrobial and tissue-repair activity makes it a natural fit for studies examining both processes together rather than in isolation.
Research Applications: Skin Conditions and Beyond
LL-37 shows up across a range of research areas connected to skin barrier function and systemic inflammation:
- Psoriasis research — LL-37 has been studied for its role in triggering autoimmune inflammatory cascades in psoriatic skin
- Rosacea research — abnormal cathelicidin processing has been examined as a contributing mechanism
- Atopic dermatitis research — studied in relation to skin barrier and antimicrobial deficiency
- Sepsis research — LL-37's LPS-binding activity is studied in the context of systemic inflammatory response
These research applications are referenced here strictly at the literature level. LL-37 research peptides sold for laboratory use are not intended to diagnose, treat, or cure any of the conditions studied in connection with the compound.
Purity, Storage & Reconstitution for LL-37 Research Peptide
Purity and Certificate of Analysis
As with any research peptide, LL-37's usefulness in a laboratory setting depends entirely on verified purity and identity. A credible LL-37 certificate of analysis (COA) should come from an independent third-party lab and include:
- Purity percentage confirmed by HPLC
- Molecular weight/identity confirmation via mass spectrometry
- Batch or lot number matching the vial received
- Testing lab name and test date
Storage Guidelines
- Store lyophilized LL-37 frozen and protected from light until reconstitution
- Refrigerate reconstituted peptide and use within the supplier's recommended window
- Avoid repeated freeze-thaw cycles, which accelerate peptide degradation
Reconstitution Basics
- Bring the lyophilized LL-37 vial and bacteriostatic water to room temperature
- Slowly inject the diluent down the interior wall of the vial
- Gently swirl — never shake — until fully dissolved
- Label the vial with date and concentration
- Store per the supplier's documentation and use within the recommended timeframe
A peptide reconstitution calculator takes the guesswork out of step 3 by converting vial size and desired concentration into an exact diluent volume — helpful for keeping LL-37 concentrations consistent across a research protocol.
How to Choose a Reliable LL-37 Peptide Supplier
- Request a third-party COA matched to the specific batch/lot you're purchasing
- Confirm the peptide sequence and molecular weight are explicitly stated, not just a purity percentage
- Look for clear RUO labeling with no human-use dosing language
- Ask about manufacturing standards and US-based sourcing
- Check for a documented quality-issue or batch-replacement policy
Key Takeaways
- LL-37 is a 37-amino-acid cathelicidin-family host-defense peptide, cleaved from the precursor protein hCAP-18
- Its amphipathic alpha-helical structure drives both its membrane-disrupting antimicrobial activity and its immune-signaling role
- Research applications span antimicrobial and biofilm studies, anti-inflammatory and immune-modulation research, and wound-healing models
- LL-37 differs structurally and functionally from human defensins, though both are studied as host-defense peptides
- Skin and systemic research areas connected to LL-37 include psoriasis, rosacea, atopic dermatitis, and sepsis research — referenced at the literature level only
- A trustworthy LL-37 research peptide requires a batch-matched third-party COA with both HPLC and mass spectrometry data
- Proper storage and careful reconstitution protect both peptide integrity and research consistency
Frequently Asked Questions
What is LL-37?
LL-37 is a 37-amino-acid host-defense peptide from the cathelicidin family, studied for antimicrobial, immune-modulating, and wound-healing properties in laboratory research.
What is LL-37 used for in research?
LL-37 is studied for its antimicrobial activity against bacteria and biofilms, its role in immune modulation and inflammation, and its involvement in wound-healing and skin-barrier research.
What is a cathelicidin?
A cathelicidin is a class of host-defense peptide found across many species; LL-37 is the only cathelicidin peptide expressed in humans.
How does LL-37 kill bacteria?
LL-37's positively charged, amphipathic structure binds to negatively charged bacterial membranes and inserts into the lipid bilayer, disrupting membrane integrity and causing bacterial cell death.
Does LL-37 have anti-inflammatory properties?
LL-37 is studied for immune-modulating activity, including chemoattractant effects on immune cells and interaction with formyl peptide receptor 2, alongside its antimicrobial role.
What role does LL-37 play in wound-healing research?
LL-37 is studied for effects on keratinocyte proliferation, angiogenesis, and tissue regeneration, making it relevant to both infection control and repair processes in wound-healing models.
Is LL-37 the same as hCAP-18?
No. hCAP-18 is the inactive precursor protein; LL-37 is the active peptide released after hCAP-18 is cleaved by proteinase 3.
What is the difference between LL-37 and defensins?
LL-37 is a cathelicidin with an alpha-helical structure, while defensins are a separate peptide family with a beta-sheet structure stabilized by disulfide bonds. Both are antimicrobial host-defense peptides but differ in structure and source cells.
How is LL-37 peptide reconstituted for lab use?
Bring the vial and bacteriostatic water to room temperature, slowly inject the diluent down the vial wall, gently swirl until dissolved, then label and store per the supplier's guidance.
What purity level should research-grade LL-37 have?
Look for a supplier-documented purity percentage backed by a third-party certificate of analysis showing both HPLC and mass spectrometry results for the specific batch.
How should LL-37 peptide be stored?
Store lyophilized LL-37 frozen and protected from light; refrigerate reconstituted peptide and use within the supplier's recommended timeframe, avoiding repeated freeze-thaw cycles.
What does an LL-37 certificate of analysis show?
A complete COA shows the peptide sequence, purity percentage with HPLC data, molecular weight confirmation via mass spectrometry, batch/lot number, and testing lab and date.
Is LL-37 legal to purchase for research in the USA?
Yes, LL-37 sold as an RUO-labeled research peptide for legitimate laboratory research is legal to purchase in the United States, provided it is not marketed or sold for human use.
Which receptor does LL-37 bind to?
LL-37 has been studied interacting with formyl peptide receptor 2 (FPR2) on immune cells, among other signaling pathways relevant to chemotaxis and inflammation.
Can LL-37 disrupt bacterial biofilms?
LL-37 has been studied for its ability to interfere with biofilm formation and disrupt existing biofilms, structured bacterial communities that resist conventional antibiotics.
